Recent Updates — NBIX
Neurocrine Biosciences announced that Sanjay Keswani, M.D., will depart as Chief Medical Officer effective September 25, 2026, following a mutual agreement with the Board. Eiry W. Roberts, M.D., has been appointed to succeed him, effective September 28, 2026. Dr. Roberts’ compensation package includes an annual base salary of $825,000 and a target cash incentive bonus equal to 60% of her base pay. Her equity grants total approximately $1.25 million, comprising stock options ($625,000), restricted stock units ($250,000), and performance-vesting restricted stock units ($375,000). Dr. Keswani is entitled to severance benefits under the Company’s Executive Severance Plan. Neurocrine Biosciences operates in the biotechnology industry, focusing on the discovery and development of therapies for neurological and endocrine disorders.
Neurocrine Biosciences filed an amendment to its Form 8-K to include audited financial statements for acquired entity Soleno Therapeutics and unaudited pro forma combined income statements. The filing confirms the completion of the acquisition on May 18, 2026, at a cash price of $53.00 per share. Neurocrine also entered into a five-year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase Bank to fund working capital needs post-acquisition. The company drew and subsequently repaid $600 million under this facility by June 30, 2026. Pro forma results indicate combined revenues of $1.9 billion for the six months ended June 30, 2026, and $3.1 billion for the year ended December 31, 2025. Neurocrine Biosciences operates in the biotechnology industry, developing and commercializing innovative medicines for central nervous system disorders.
Neurocrine Biosciences reported second-quarter 2026 financial results with total revenues of $959 million, a 39% increase year-over-year from $688 million. GAAP diluted earnings per share were $1.39, compared to $1.06 in the prior year period. The company raised its full-year 2026 INGREZZA net product sales guidance to $2.825–$2.875 billion from a previous range of $2.7–$2.8 billion. Neurocrine completed its acquisition of Soleno Therapeutics in May 2026 for $2.9 billion, adding VYKAT XR to its portfolio, and entered into a $1.0 billion senior secured revolving credit facility. The biopharmaceutical company discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders.